Celsion Corp Gets a Hold from Maxim GroupBy Jason Carr
“Celsion announced that the company will present updated data from the P1b Ovation study evaluating GEN-1 (DNA-based IL-12) in advanced ovarian cancer at ASCO (American Society of Clinical Oncology, June 2-6, 2017).”
According to TipRanks.com, McCarthy is ranked 0 out of 5 stars with an average return of -12.2% and a 34.5% success rate. McCarthy covers the Healthcare sector, focusing on stocks such as ImmunoCellular Therapeutics, Mateon Therapeutics Inc, and Stellar Biotechnologies.
Celsion Corp has an analyst consensus of Moderate Buy.
Based on Celsion Corp’s latest earnings report for the quarter ending December 31, the company posted quarterly revenue of $125K and GAAP net loss of $5.4 million. In comparison, last year the company earned revenue of $125K and had a GAAP net loss of $5.72 million.
Based on the recent corporate insider activity of 11 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of CLSN in relation to earlier this year. Most recently, in February 2017, Alberto Martinez, a Director at CLSN bought 35,000 shares for a total of $8,050.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Celsion Corp. is an oncology drug development company focused on developing a portfolio of innovative cancer treatments, including directed chemotherapies, DNA-mediated immunotherapy and RNA- based therapies. Its products include Celsion, ThermoDox, EGEN, TheraPlas and TheraSilence. The company was founded by Yim-Pan Cheung in 1982 and is headquartered in Lawrenceville, NJ.